COGT — Cogent Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1622229 ·
Last close
$32.31
Market Cap
$5.61B
52W High
$43.73
52W Low
$13.30
ADV30
1,845,120
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -102,638,000 | -96,405,000 | 834,546,000 | 181,172,000 | 302,158,000 |
| Mar 2026 | 0 | — | -103,607,000 | -97,352,000 | 903,006,000 | 241,208,000 | 295,313,000 |
| Dec 2025 | 0 | — | -99,493,000 | -102,492,000 | 937,607,000 | 312,012,000 | 301,236,000 |
| Sep 2025 | 0 | — | -83,355,000 | -80,930,000 | 425,933,000 | 125,297,000 | 123,469,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-284,816,000
Investing CF
$-505,362,000
Financing CF
$905,799,000
CapEx
$-1,456,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.43
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,285,772,000
Inventory
—
Receivables
—
ST Investments
$625,170,000
EBIT TTM
$-350,028,000
Pretax Income TTM
$-354,303,000
Interest Exp TTM
$4,275,000
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -333,363,000 | -328,937,000 | 937,607,000 | 301,236,000 | 636,371,000 | -264,444,000 |
| Dec 2024 | 0 | -275,939,000 | -255,859,000 | 327,898,000 | 71,612,000 | 256,286,000 | -207,791,000 |
| Dec 2023 | 0 | -208,130,000 | -192,410,000 | 313,437,000 | 55,635,000 | 257,802,000 | -153,624,000 |
| Dec 2022 | 0 | -147,839,000 | -140,241,000 | 300,810,000 | 45,075,000 | 255,735,000 | -118,638,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.09
Max Pain — expiry 2027-01-15
max pain strike: $30.00 · spot: $32.31 · call oi: 7,841 · put oi: 954
Expected Move to 2027-01-15:
±$7.80
(24.14%) —
implied range
$24.51 –
$40.11
· ATM straddle on $32.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | $5.60B | $59.44 | — |
| ORKA | Oruka Therapeutics, Inc. | $5.59B | $84.46 | — |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.82B | $89.70 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.23B | $62.67 | — |
| LGND | LIGAND PHARMACEUTICALS INC | $6.01B | $301.52 | — |
News headlines (Yahoo Finance, 1h cache)
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
2026-09-25 10:10 · Yahoo
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
2026-09-24 18:12 · Yahoo
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
2026-09-24 12:11 · Yahoo
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
2026-09-15 12:00 · Yahoo
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
2026-06-30 12:00 · Yahoo
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?
2026-06-22 14:14 · Yahoo
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial
2026-06-12 12:58 · Yahoo
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
2026-06-12 12:01 · Yahoo
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
2026-06-12 12:00 · Yahoo
How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen
2026-06-10 02:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.